Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | PRKX | P51817 | 2/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750671 | 0.85 | THRB (0.45) | CYP2C9KDM4EMAOAALDH1A1MAPT | |
| SCHEMBL7134254 | 0.71 | MMP13 (0.86) | PRKACAPRKXPRKCQROCK1MMP13 | |
| SCHEMBL9416645 | 0.70 | MMP13 (0.94) | PRKACAPRKXPRKCQROCK1GRK5 | |
| SCHEMBL8345252 | 0.70 | SMN1; SMN2 (0.52) | MMP13LMNAALDH1A1MAPTMAPK1 | |
| SCHEMBL2922655 | 0.69 | MMP13 (0.81) | MMP13LMNAHPGDAURKAALDH1A1 | |
| SCHEMBL13450237 | 0.68 | MMP13 (0.67) | PRKACAPRKXPRKCQROCK1GRK5 | |
| SCHEMBL3402865 | 0.68 | MMP13 (0.67) | PRKACAPRKXPRKCQROCK1GRK5 | |
| SCHEMBL31061610 | 0.68 | MMP13 (1.00) | PRKACAPRKXPRKCQROCK1GRK5 | |
| SCHEMBL5332068 | 0.68 | MMP13 (1.00) | PRKACAPRKXPRKCQROCK1GRK5 | |
| SCHEMBL6919620 | 0.68 | MAPT (0.43) | CYP3A4CYP2D6CYP2C9LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2004-03-04 | — | — | US | claimed |
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014389-A1 | 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014389-A1 | 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP3 | PRKACA 2391/4885PRKX 2431/4885PRKCQ 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.